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ABSTRACT The a13-adrenergic receptor (a01-ADR) is a
member of the G-protein-coupled family of transmembrane
receptors. When transfected into Rat-i and NIH 3T3 fibro-
blasts, this receptor induces focus formation in an agonist-
dependent manner. Focus-derived, transformed fibroblasts
exhibit high levels of functional alB-ADR expression, demon-
strate a catecholamine-induced enhancement in the rate of
cellular proliferation, and are tumorigenic when injected into
nude mice. Induction of neoplastic transformation by the
alB-ADR, therefore, identifies this normal cellular gene as a
protooncogene. Mutational alteration of this receptor can lead
to activation of this protooncogene, resulting in an enhanced
ability of agonist to induce focus formation with a decreased
latency and quantitative increase in transformed foci. In con-
trast to cells expressing the wild-type alB-ADR, focus forma-
tion in "oncomutant"-expressing cell lines appears constitu-
tively activated with the generation offoci in unstinulated cells.
Further, these cell lines exhibit near-maximal rates of prolif-
eration even in the absence of catecholamine supplementation.
They also demonstrate an enhanced ability for tumor genera-
tion in nude mice with a decreased period of latency compared
with cells expressing the wild-type receptor. Thus, the aIB-
ADR gene can, when overexpressed and activated, function as
an oncogene inducing neoplatic ranformation. Mutational
alteration of this receptor gene can result in the activation of
this protooncogene, enhancing its oncogenic potential. These
findings suggest that analogous spontaneously occurring mu-
tations in this class of receptor proteins could play a key role
in the induction or progression of neoplastic transformation
and atherosclerosis.
Cellular oncogenes originate by the activation of normal
cellular genes with latent transforming potential (i.e., pro-
tooncogenes) and subvert key regulatory pathways control-
ling cell proliferation. Several oncogenes have been shown to
encode for altered receptor proteins, including c-fms, erbB,
kit, neu, ros, and mas (1-4), and some have also been
associated with human malignancies (5-7). The known cel-
lular homologues of these mutant receptors belong to differ-
ent receptor classes based on their structural features and
coupling to specific signal transduction pathways. The mas
oncogene, for example, bears structural homology to the
broad superfamily of guanine nucleotide-binding protein (G-
protein)-coupled receptors (8); transmembrane receptors
that transduce extracellular stimuli through G-protein inter-
mediates.
Multiple mechanisms exist for modulating the transforming
potential of protooncogenes including mutational change;
e.g., a point mutation in the ras family of protooncogenes
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FIG. 1. Structural model ofthe alB-ADR, with an enlarged region
illustrating the carboxyl terminus of the third intracellular loop and
the sixth transmembrane domain. Solid circles indicate the amino
acids of the wild-type a1B-ADR that were mutated (positions 288,
290, and 293); the amino acid residues replaced in the aiB-ADR
mutant are shown to the right. Crosses represent potential glycosy-
lation sites near the amino terminus.
converts them to actively transforming oncogenes (9, 10).
Such mutations can activate protooncogenes by altering their
level of expression or by modifying key regulatory domains,
resulting in constitutive activity.
We previously reported (11) that mutational alteration of
one of the adrenergic receptors (Fig. 1), the a1B-adrenergic
receptor (aIn-ADR), markedly alters agonist binding affinity
and potency in activating intracellular signaling pathways
(11). This receptor is a member of the G-protein-coupled
receptor superfamily (12) and activates phosphatidylinositol
(PI) hydrolysis; a signaling pathway that appears to play a
crucial role in mitogenesis (13, 14). Substitution of residues
at the carboxyl terminus of the third intracellular loop of the
alB-ADR (Argm -- Lys, Lys' --) His, and Ala3 -* Leu)
results in an increase in both the binding affinity of norepi-
nephrine (NE) and its potency to stimulate PI hydrolysis by
2-3 orders of magnitude. In addition, this activating mutation
appears to render the a1B-ADR constitutively active, result-
ing in the stimulation of PI hydrolysis in the absence of
agonist-induced receptor activation. This effect was ob-
served in cells expressing the a1B-ADR mutant in both the
presence and the absence of serum (11), excluding receptor
activation by small quantities ofendogenous catecholamines.
Furthermore, single amino acid substitutions at residue 293
Abbreviations: ADR, adrenergic receptor; PI, phosphatidylinositol;[1251]HEAT, 2-{p-(4-hydroxy-3-_[25I]iodophenyl)ethylaminomethyl}-
tetralone; NE, norepinephrine.
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appear sufficient to increase the affinity and potency of NE
and to induce constitutive activity (11, 30). Several subfam-
ilies of G-protein-coupled receptors that also activate PI
hydrolysis, the serotonin (1C) and muscarinic cholinergic
(ml, m3, and m5) receptors, have been shown to result in
conditional, agonist-dependent transformation (15, 16).
Therefore, we investigated whether constitutively activating
mutations, such as the one we described for the alB-ADR,
might serve as a mechanism for activating G-protein-coupled
receptor protooncogenes, thereby enhancing their ability to
subvert normal signaling pathways, and result in neoplastic
transformation independent of agonist supplementation.
MATERIALS AND METHODS
Cell Culture. Rat-1 fibroblasts were grown in Dulbecco's
modified Eagle's medium (DMEM) containing 5% (vol/vol)
fetal bovine serum and gentamicin (100 jug/ml). For selec-
tion, cells were cultured in the presence of a neomycin
analogue, G418 sulfate (300 ,.g/ml; GIBCO).
Expression Plasmids. The cDNAs of the hamster alB-ADR
(17), alB-ADR mutant (11), and activated Ha-ras were sub-
cloned by 'blunt-ended ligation into the BamHI site of the
retroviral expression vector pZIP-NeoSV(X)1 (18). This re-
combinant plasmid contains strong promoter and enhancer
elements in the Moloney murine leukemia virus long terminal
repeats and carries the selectable drug-resistance gene for
aminoglycoside phosphotransferase.
DNA Transfection. Subconfluent cells were transfected
with 10 ,.g of the recombinant expression plasmids by the
calcium phosphate precipitation method (19). After 16 hr, the
DNA precipitate was removed, and the cells were washed
and then grown for 24 hr in complete medium.
Focus-Formation Assays. Rat-i fibroblasts were seeded at
a density of 2 x i0s cells in 100-mm dishes. Cells were grown
overnight, then transfected with expression vector alone or
containing the aie-ADR, alB-ADR mutant, or activated
Ha-ras cDNA inserts as described above. The following day,
they were split 1:5, allowed to attach overnight, and then
cultured in the presence or absence of 10 ,uM NE in DMEM
with 5% fetal bovine serum. Dishes were supplemented-with
NE daily, fed every 3 days with fresh medium, and scored
after 4 weeks of culture.
Ligand Binding. Ligand binding was assayed on mem-
branes prepared from stably transfected Rat-i fibroblast cell
lines (20). For saturation binding analysis, concentrations of
2-{J-(4-hydroxy-3-[125I]iodophenyl)ethylaminomethyl}tetra-
lone ([251I]HEAT) ranged from 10 to 500 pM, and nonspecific
binding was determined using 1 ,uM prazosin; in competition
experiments, the radioligand concentration was 100 pM.
Ligand binding parameters were determined using comput-
erized iterative nonlinear regression analysis (21). For ligand
binding studies on tumor tissue, animals were sacrificed and
tissue was rapidly excised and frozen in liquid nitrogen.
Tissue fragments were resuspended in 50 mM Tris buffer (pH
7.4) containing 150 mM NaCI, 5 mM EDTA, trypsin inhibitor
(10 ug/ml), leupeptin (10 ,ug/ml), and bacitracin (200 jug/m1)
and were homogenized with a Polytron (Brinkmann) at
maximum speed. The particulate fraction was pelleted by
centrifugation at 19,000 x g for 10 min, washed once, and
Dounce homogenized, and the membranes were used for
ligand binding.
Inositol Phosphate Determination. Cells were plated in
30-mm dishes and incubated overnight with myo-[2(N)-
3H]inositol (3 ,uCi/ml; 1 Ci = 37 GBq; New England Nuclear)
in DMEM containing 3.3% fetal bovine serum, as described
(11). After stimulation, inositol phosphates were extracted,
and separated on AG 1-X8 anion-exchange columns (Bio-
Rad). Total inositol phosphates were eluted with 1 M am-
monium formate/0.1 M formic acid.
Cell Growth. Cells were plated in 100-mm dishes at a
density of5 x 101 cells per dish in DMEM containing 5% fetal
bovine serum. After 24 hr, half the dishes received daily
supplementation with 10 juM NE, and all the dishes received
fresh medium every 2-3 days. At each time point, cells were
trypsinized and cell counts were determined with an elec-
tronic particle counter (Coulter).
Tumorigenesis. Rat-i fibroblasts and G418-selected fibro-
blast cell lines were cultured in the presence of 10 puM NE for
14 days. Cells were trypsinized, washed, and resuspended in
serum-free DMEM, and then 5 x 106 cells were injected at
two sites in 21- to 28-day-old female nu/nu CD-1 mice
(Charles River Breeding Laboratories). Animals were mon-
itored at 2- to 3-day intervals for the development of tumors
over a 4- to 8-week period.
RESULTS AND DISCUSSION
aIB-ADR Expression Results in Agonist-Dependent Focus
Formation. The functional consequences of receptor expres-
sion on cell growth were assessed after transfection of Rat-i
fibroblasts with the alB-ADR recombinant plasmid. In the
absence of added agonist, no change in phenotype or focal
cell overgrowth was observed after 4 weeks in culture (Fig.
2A). The cells formed a uniform monolayer in culture and
became arrested through contact inhibition. However, ago-
nist (NE) stimulation reproducibly resulted in the induction
of the transformed phenotype' with focus formation in con-
fluent monolayers within 2-3 weeks (Fig. 2B). Within foci,
cells manifested the malignant phenotype with the loss of
normal density-dependent growth inhibition, resulting in
increased cellular packing, refractility, and a disordered
cellular orientation. Focus formation was strictly agonist-
dependent and was not observed in untransfected fibroblasts
or those transfected with expression vector alone. The initial
frequency of agonist-induced focus formation in Rat-1 fibro-
blasts was low when compared with focus formation resulting
from transfection with the activated ras oncogene (Table 1).
Agonist-induced foci represented 15-25% of transfected
clones with the number of G418-resistant colonies (40-60 per
dish) assessed in duplicate transfections. Parallel experi-
ments employing NIH 3T3 mouse fibroblasts resulted in a
marked increase in the frequency of agonist-induced focus
formation (Table 1) with no significant change 'in the trans-
fection efficiency. These cells, however, also exhibited ahigh
background of spontaneous transformation in control and
untreated cells.
The ability of catecholamines to induce neoplastic trans-
formation of fibroblasts transfected with the alB-ADR sug-
gests a role for the'receptor in regulating mitogenesis and
identifies its gene as a protooncogene. While oncogenes, the
activated form of protooncogenes, are capable of inducing
transformation with high efficiency, their precursors are less
A 2Ao
FIG. 2. Agonist-dependent transformation of Rat-1 fibroblasts
transfected with GlB-ADR cDNA. Rat-1 fibroblasts were transfected
with aretroviral expression vector, pZIP-NeoSV(X)1, containing the
aln-ADR cDNA. Cells were then cultured for 4 weeks in the absence
(A) or presence (B) of 10 ,uM NE. (x 6.)
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Table 1. Focus formation in Rat-1 and NIH 3T3 fibroblasts
transfected with expression vector pZIP-NeoSV(X)l alone or
containing the alB-ADR, ajB-ADR mutant, or ras cDNA inserts
No. of foci
Rat-1 NIH 3T3
DNA -NE +NE -NE +NE
Vector 0 0 10 12
alB 0 8 12 85
ama mutant 0 11 ND ND
ras 206 197 160 180
Cells were cultured in the presence or absence of 10 IAM NE, as
described in Materials andMethods. The number oftransformed foci
was scored after 4 weeks of culture. Results represent the average of
duplicate determinations from two independent experiments, which
agreed within 25%. ND, not determined.
Table 2. Focus formation in focus-derived Rat-i fibroblast lines
No. of foci
DNA -NE +NE
Vector 0 0
o 0
alB 0 75
0 80
aIB mutant 45 >500, sheets
65 >500, sheets
ras >500 >$00
450 460
Cell lines were established from cells transfected with the expres-
sion vector pZIP-NeoSV(X)l alone or from separate transformed
foci of Rat-i fibroblasts transfected with vector containing the
alB-ADR, aIB-APR mutant, or ras cDNAs; two clones are Khown for
each. Cells were cultured in the presence or absence of 10 ,.M NE,
competent or may even be incompetent. Thus, the number of nu te numoer Il I0Ci was SCCreu aier.J weeas. iwsuitS representthe mean of duplicate determinations from two independent exper-foci initially generated by constant agonist stimulation may imen whicage within20%.be a reflection of the relatively low intrinsic activity of the
unactivated receptor protooncogene. Alternatively, in vitro This disordered pattern ofgrowth was blocked by concurrent
transformation may require collaboration of oncogenes (22). incubation of the cells with prazosin,- which reverted the cells
Agonist-induced receptor activation'may, therefore, function to the untransformed phenotype (Fig. 3C). These results
to complement preexisting activated protooncogenes in these confirm the conditional nature of transformation 'of Rat-1
cells, representing a "second hit" phenomenon. fibroblasts by the alB-ADR, a process requiring continuous
Maintenance of the Transfortned Phenotype Requires Con- agonist-induced receptor activation.
tinuous Receptor Activation. The dependency of focus for- Mutational lteration of the alr-AD1R Results in Protoon-
mation on both transfection with amB-ADR cDNA and con- cogene Activation. Having established' that the acB-AIPR
tinuous activation of this receptor by catecholamines impli- could function as a protooncogene, we investigated whether
cates the alB-ADR in activating transmembrane signaling mutational altetation of this receptor (Fig. 1),which induces
pathways that result in cellular transformation. MVItiple cell constitutive activity, would result in protooncogene activa-
lines established from individual foci of, transformed Rat-1 tion and enhance the oncogenic potential of the a'1B-ADR.
fibroblasts, however, showed no spontaneous focus forma- Transfection of Rat-i fibroblasts with the expression plaomid
tion when maintained in culture in the absence of added containing the, alB-ADR mutant cDNA resulted in malignant
agonist (Table 2). On reexposure to agonist, however, these transformation with focus formation in vitro at initial rates
cells showed a markedly enhanced ability for focus genera- comparable to those of cells expressing the wild-type' recep-
tion, inducing transformed foci at significantly increased tor (Table 1). Restimulation of focus-derived cell lines 'with
rates within 2-3 weeks (Table' 2). Focus formation remained agonist, however, resulted in an enhanced ability for focus
strictly agonist-dependent and could be inhibited by concur- generation' with a quantitative increase in focus number
rent administration of the selective a1-antagonist'prazosin (Table 2); the amB-ADR mutant-transfected cells attained(data not shown). The absence of focus formation in unstim- rates of focus formation comparable to that of the activated
ulated focus-derived cells provides evidence for the essential ras oncogene. In addition, the latency period to focus for-
role of receptor activation in maintenance of the transformed mation was decreased in these cell lines, with foci appearing
phenotype. within 7 days compared with'14-21 days in cells transfected
Morphologically, cells expressing the alm-APR exhibited with the wild-type receptor. Further, while focus formation
the normal phenotype, when cultured in the absence of was markedly augmented by agonist administration, it was
catecholamines (Fig. 3A). In contrast, the same cells, when not absolutely agonist-dependent with the generation of foci
grown in the presence of NE, 'demonstrated' an agonist- in unstinmulated cells (Table 2). Morphologically, these cells
dependent alteration in cellular morphology with a loss in formed broad sheet-like plaques of transformed cells, rather
cellular orientation and decreased' adhesiveness (Fig. 3B). than the'discrete focal cell overgrowths seen in cells express-
A
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FIG. 3. Agonist-dependent transformation of Rat-1 fibroblasts transfected with the amB-ADR cDNA. The morphology of a representative
Rat-i fibroblast line derived from a single transformed focus expressing the a1B-ADR is shown. Cells were grown in the absence of added ligand(A), in the presence of 10 AM NE (B), or in the presence of 10 AM NE and 1 AM prazosin (C) for 36 hr. (x -45.)
Proc. Nad. Acad. Sci. USA 88 (1991)
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Table 3. Parameters of ligand binding and activation of PI
hydrolysis in Rat-1 fibroblast lines expressing the alB-ADR
or a1B-ADR mutant
Ligand binding*
NE [12I]HEAT NE-stimulated
K;, Kd, Ban, PI hydrolysis,
Receptor nM pM pmol/mg % increaset
Vector 0 0
--0 0
a1B 5815 44.1 5.1 758
5333 38.3 2.7 410
a1B mutant 42 37.9 2.2 861
47 46.3 2.6 954
*NE and ['25I]HEAT binding were assessed as described in Mate-
rials and Methods.
VPercent increase of total labeled inositol phosphates over basal
levels following stimulation with 10 ,uM NE for 30 min. Results
represent the mean of triplicate determinations of two to three
independent experiments, which agreed within 20%o.
ing the wild-type alB-ADR (data not shown). These cell lines,
therefore, appear constitutively activated, exhibiting the
malignant phenotype independent of agonist supplementa-
tion. In addition, NE-induced focus formation is significantly
augmented in these lines, reaching the levels observed with
the known oncogene ras. Because of this enhanced trans-
formed phenotype of the acB-ADR mutant-transfected cell
lines, this mutant receptor was termed the "oncomutant."
Conservative mutational alteration of the alB-ADR, thus,
appears to activate the transforming activity of this protoon-
cogene, enhancing its oncogenic potential.
alB-ADR Overexpression and Activation ofTransmembrane
Signaling Pathways in Transformed Foci. Cell lines estab-
lished from foci of transformed Rat-i fibroblasts exhibited
high levels ofa,'-ADR expression as assessed by the binding
of the a1-ADR antagonist [11I]HEAT. Receptor concentra-
tions were in the range of 3-5 pmol/mg of protein in various
clones (Table 3), representing an -10-fold higher level of
receptor expression than in tissues normally expressing this
receptor. The Kd of [125IJHEAT and Ki of NE were in
agreement with values established for this receptor (17). Cell
lines derived from foci arising after transfection with the
a1B-ADR mutant demonstrated receptor expression at %-2
pmol/mg of protein (Table 3) and exhibited the enhanced
agonist affinity previously reported (11). Untransfected Rat-1
fibroblasts or cells transfected with vector alone, on the other
hand, showed no specific binding. Therefore, the cells giving
rise to transformed foci overexpressed the alB-ADR, estab-
lishing a role for this receptor in mediating the process of
neoplastic transformation.
Since Rat-i fibroblasts do not normally express the aeB-
ADR, their ability to mediate functional coupling of this
10
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receptor to PI hydrolysis was investigated. In focus-derived
fibroblasts, as in cells that normally express the alB-ADR,
receptor activation resulted in phospholipase C-mediated PI
hydrolysis with a 400-800o increase in total inositol phos-
phates following NE stimulation (Table 3). In cell lines
expressing the a1B-ADR mutant, NE induced a 900-100%o
increase in -inositol phosphates (Table 3); this level of PI
hydrolysis was seen only in cells expressing the wild-type
receptor with a 2-fold higher level of receptor expression. In
contrast, no coupling was observed in cells transfected with
vector alone or in wild-type Rat-1 fibroblasts, which lack the
receptor. The alB-ADR, appearing on the surface of Rat-i
fibroblasts following transfection, therefore, functionally
couples to PI hydrolysis in these cells. Whether receptor
coupling to phospholipase C actually mediates the alB-
ADR's ability to induce malignant transformation in these
cells remains speculative, however. Coupling ofthis receptor
to alternative G proteins or effector systems may be respon-
sible for triggering uncontrolled cell proliferation.'
Oncomutant-Expressing Ceil Lines Exhibit a Enhanced
Rate of Mitogeneis. Focus formation represents a morpho-
logic manifestation of agonist-induced transformation and
implies the loss of contact inhibition, 'a normal growth
regulatory process. To quantitate receptor-mediated effects
on mitogenesis, basal and NE-stimulated growth rates were
assessed' on cell lines expressing the wild-type or mutant
alB-ADRs. Control, vector-transfected cells showed no sig-
nificant difference in the rate of cell proliferation in the
presence or absence of catecholamines (Fig. 4A). In the
absence of NE, a1B-ADR-expressing cells grew at nearly
control levels, reaching the same- saturation density as con-
trol cells by day 25. The addition of catecholamines to these
cells, however, resulted in an augmented rate of cell prolif-
eration, surpassing control levels by day 12 and reaching a
final cell density (day 25) that was 1.9 times control levels
(Fig. 4B). Thus, catecholamines appear to be competent
mitogens in these cells acting through the alB-ADR. The
ability of NE alone to induce an 11-fold increase in DNA
synthetic activity in serum-free medium provides additional
evidence for a direct mitogenic effect of catecholamines; an
effect that could be blocked by prazosin, but not by a2
(idazoxan or yohimbine) or /3 (propranolol) adrenergic re-
ceptor antagonists (data not shown).
Oncomutant-expressing cell lines demonstrated a more
pronounced mitogenic response than was observed in ago-
nist-stimulated cells expressing the wild-type a1B-ADR (Fig.
4C). They exhibited a significantly shortened doubling time,
with cell counts surpassing control levels earlier (day 8), and
a 3-fold increase in final cell density compared with control
cells. In addition, proliferative activity in these cell lines was
maximally activated even in the absence of catecholamine
supplementation. Protooncogene activation, therefore, not
only resulted in the loss of contact inhibition but also en-
hanced the rate of mitogenesis in the focus-derived cell lines.
8 16
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FIG. 4. Growth curves of representative G418-selected Rat-1 fibroblast lines transfected with vector alone (A) or expressing the alB-ADR
(B) or a1B-ADR mutant (C) in the absence (-) or presence (---) of 10 AM NE. Values represent the mean of duplicate determinations of a
representative experiment, which agreed within 6%.
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The faster doubling time and greater saturation densities of
cell lines expressing the aiB-ADR mutant suggests that these
cells exhibit a more aggressive malignant phenotype. Muta-
tional alteration of the alB-ADR, through amino acid substi-
tution in'the third cytoplasmic loop, thus appears to result in
the activation of this G-protein-coupled receptor protoonco-
gene. Oncomutant-expressing cell lines appear constitutively
active with focus formation and maximal growth rates inde-
pendent of agonist administration.
Transformed Foci Possess Tumorigenic Potential in Nude
Mice. In vitro assays of transformation do not always trans-
late into tumorigenic potential in vivo. In vivo tumorigenesis
assays employing nude mice provide a more sensitive assay
of true oncogenic potential (23). Subcutaneous inoculation of
four focus-derived cell lines expressing the aiB-ADR into
CD-1 nude mice reproducibly resulted in tumorigenesis with
the generation of fibrosarcomas in >90%6 (11/12) of tested
animals after 3 weeks. Four cell lines expressing the alB-ADR
mutant also induced tumors when injected (16/16) and further
demonstrated an enhanced ability for tumorigenesis with a
decreased period of latency (2 weeks versus 3 weeks), tumor
formation in the absence ofNE priming, and increased tumor
size compared with lines expressing the wild-type receptor.
No tumors were observed with injection of Rat-i fibroblasts
or fibroblasts transfected with vector alone after 8 weeks.
Examination of the tumor tissue revealed alB-ADR expres-
sion with receptor concentrations in the range of 0.5-6
pmol/mg of protein. Activation of the alB-ADR, therefore, is
able to induce a cascade of biochemical and physiological
events that result in the transformation of Rat-1 fibroblasts to
cells that are tumorigenic in vivo. Mutational activation of
this protooncogene augments its oncogenic potential, result-
ing in a marked enhancement of cell growth and tumorigen-
esis.
The a1B-ADR Gene Can Function as a Protooncogene and Be
Activated by Mutational Alteration. These studies directly
demonstrate the potential of the alB-ADR to activate signal
transduction pathways that can abrogate normal growth
control mechanisms. Expression of functional a1B-ADRs
induces neoplastic transformation of rat and mouse fibro-
blasts in an agonist-dependent manner to cells possessing
tumorigenic potential. Overexpression and agonist-induced
activation of the a1B-ADR leading to cellular transformation
identifies it as the product of a protooncogene, a cellular gene
with a latent potential for inducing neoplastic transformation.
The broad distribution and'prominent functional role of the
aiB-ADR in several body systems [e.g., hepatic regeneration
(24)] suggests a potential role for this G-protein-coupled
receptor protooncogene in tumorigenesis. In addition, the
mitogenic effect of catecholamines on vascular smooth mus-
cle (25, 26) and the ability of the a1B-ADR to modulate cell
proliferation may implicate the receptor in the pathogenesis
of atherosclerosis.
Mutational alteration of the alB-ADR that renders it con-
stitutively active appears to activate the transforming poten-
tial of this protooncogene and plays an important role in
triggering uncontrolled cell proliferation in vitro. G-protein-
coupled receptors have now emerged as a class of growth
factor receptors that can modulate signaling pathways that
control cell proliferation (27-29). Given the highly conserved
structural features of these receptors and the demonstrated
ability of several of them to mediate mitogenesis and trans-
formation (15, 16, .8, 29), the potential exists for a common
mechanism of activation that converts these genes to onco-
genes. Mutational alteration of key amino acids in the car-
boxyl terminus of the third intracellular loop, important for
receptor/G-protein coupling, may prove to be a generalized
mechanism for inducing constitutive activity and activating
this class of G-protein-coupled receptor protooncogenes.
Spontaneously occurring mutations of this type in this or
other structurally related receptor genes in vivo, therefore,
may subvert the normal function ofthese receptors and result
in human disease states associated with uncontrolled cell
growth, including neoplasia and atherosclerosis. In addition,
identification of such mutant receptors may provide specific
disease markers and pharmacologic targets for therapeutic
intervention.
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